Kane RC , Bross PF, Farrell AT, Pazdur R: Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. The Oncologist 8, 508–513 (2003)

Kane RC , BrossPF, FarrellAT, PazdurR: Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. The Oncologist8, 508–513 (2003))| false
• Search Google Scholar
• Export Citation

Crawford LJ , Walker B, Irvine AE: Proteasome inhibitors in cancer therapy. J Cell Commun Signal 5, 101–110 (2011)

Crawford LJ , WalkerB, IrvineAE: Proteasome inhibitors in cancer therapy. J Cell Commun Signal5, 101–110 (2011))| false
• Search Google Scholar
• Export Citation

Dou QP , Zonder JA: Overview of proteasome inhibitorbased anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets 14, 517–536 (2014)

Dou QP , ZonderJA: Overview of proteasome inhibitorbased anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets14, 517–536 (2014))| false
• Search Google Scholar
• Export Citation

Richardson PG , Hideshima T, Mitsiades C, Anderson K: Proteasome inhibition in hematologic malignancies. Ann Med 36, 304–314 (2004)

Richardson PG , HideshimaT, MitsiadesC, AndersonK: Proteasome inhibition in hematologic malignancies. Ann Med36, 304–314 (2004))| false
• Search Google Scholar
• Export Citation

Adams J : The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4, 349–360 (2004)

Adams J : The proteasome: a suitable antineoplastic target. Nat Rev Cancer4, 349–360 (2004))| false
• Search Google Scholar
• Export Citation

Landgren O , Iskander K: Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med [Epub ahead of print], doi: 10.1111/joim.12590 (2017)

Landgren O , IskanderK: Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med [Epub ahead of print], doi: 10.1111/joim.12590 (2017))| false
• Search Google Scholar
• Export Citation

Dou QP , Zonder JA: Overview of proteasome inhibitorbased anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets 14, 517–536 (2014)

Dou QP , ZonderJA: Overview of proteasome inhibitorbased anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets14, 517–536 (2014))| false
• Search Google Scholar
• Export Citation

Almond JB , Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433–443 (2002)

Almond JB , CohenGM: The proteasome: a novel target for cancer chemotherapy. Leukemia16, 433–443 (2002))| false
• Search Google Scholar
• Export Citation

Glickman MH , Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82, 373–428 (2002)

Glickman MH , CiechanoverA: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev82, 373–428 (2002))| false
• Search Google Scholar
• Export Citation

Goldberg AL , Akopian TN, Kisselev AF, Lee DH, Rohrwild M: New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem 378, 131–140 (1997)

Goldberg AL , AkopianTN, KisselevAF, LeeDH, RohrwildM: New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem378, 131–140 (1997))| false
• Search Google Scholar
• Export Citation

Adams J : Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6, 493–500 (2002)

Adams J : Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol6, 493–500 (2002))| false
• Search Google Scholar
• Export Citation

Adams J : The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417–421 (2004)

Adams J : The development of proteasome inhibitors as anticancer drugs. Cancer Cell5, 417–421 (2004))| false
• Search Google Scholar
• Export Citation

Hideshima T , Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61, 3071–3076 (2001)

Hideshima T , RichardsonP, ChauhanD, PalombellaVJ, ElliottPJ, AdamsJ, AndersonKC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res61, 3071–3076 (2001))| false
• Search Google Scholar
• Export Citation

Mateos MV , San Miguel JF: Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 20, 701–715 (2007)

Mateos MV , San MiguelJF: Bortezomib in multiple myeloma. Best Pract Res Clin Haematol20, 701–715 (2007))| false
• Search Google Scholar
• Export Citation

Viatour P , Merville M-P, Bours V, Chariot A: Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem Sci 30, 43–52 (2005)

Viatour P , MervilleM-P, BoursV, ChariotA: Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem Sci30, 43–52 (2005))| false
• Search Google Scholar
• Export Citation

Richardson PG , Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau J-L, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352, 2487–2498 (2005)

Richardson PG , SonneveldP, SchusterMW, IrwinD, StadtmauerEA, FaconT, HarousseauJ-L, Ben-YehudaD, LonialS, GoldschmidtH, ReeceD, San-MiguelJF, BladéJ, BoccadoroM, CavenaghJ, DaltonWS, BoralAL, EsseltineDL, PorterJB, SchenkeinD, AndersonKC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med352, 2487–2498 (2005))| false
• Search Google Scholar
• Export Citation

Oerlemans R , Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BAC, Scheper RJ, Jansen G: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112, 2489–2499 (2008)

Oerlemans R , FrankeNE, AssarafYG, CloosJ, van ZantwijkI, BerkersCR, SchefferGL, DebipersadK, VojtekovaK, LemosC, van der HeijdenJW, YlstraB, PetersGJ, KaspersGL, DijkmansBAC, ScheperRJ, JansenG: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood112, 2489–2499 (2008))| false
• Search Google Scholar
• Export Citation

Verbrugge SE , Al M, Assaraf YG, Niewerth D, Meerloo J van, Cloos J, Veer M van der, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, Gruijl TD de, Jansen G: Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol 2, 2 (2013)

Verbrugge SE , AlM, AssarafYG, NiewerthD, MeerlooJ van, CloosJ, VeerM van der, SchefferGL, PetersGJ, ChanET, AnderlJL, KirkCJ, ZweegmanS, DijkmansBA, LemsWF, ScheperRJ, GruijlTD de, JansenG: Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol2, 2 (2013))| false
• Search Google Scholar
• Export Citation

Banach M , Juranek JK, Zygulska AL: Chemotherapyinduced neuropathies-a growing problem for patients and health care providers. Brain Behav 7, e00558 (2017)

Banach M , JuranekJK, ZygulskaAL: Chemotherapyinduced neuropathies-a growing problem for patients and health care providers. Brain Behav7, e00558 (2017))| false
• Search Google Scholar
• Export Citation

Bruna J , Udina E, Alé A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L, Navarro X: Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 223, 599–608 (2010)

Bruna J , UdinaE, AléA, VilchesJJ, VynckierA, MonbaliuJ, SilvermanL, NavarroX: Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol223, 599–608 (2010))| false
• Search Google Scholar
• Export Citation

Brown MG , Driscoll J, Monaco JJ: Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 353, 355–357 (1991)

Brown MG , DriscollJ, MonacoJJ: Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature353, 355–357 (1991))| false
• Search Google Scholar
• Export Citation

Monaco JJ , McDevitt HO: The LMP antigens: A stable MHC-controlled multisubunit protein complex. Hum Immunol 15, 416–426 (1986)

Monaco JJ , McDevittHO: The LMP antigens: A stable MHC-controlled multisubunit protein complex. Hum Immunol15, 416–426 (1986))| false
• Search Google Scholar
• Export Citation

Yang Y , Waters JB, Früh K, Peterson PA: Proteasomes are regulated by interferon gamma: implications for antigen processing. Proc Natl Acad Sci U S A 89, 4928–4932 (1992)

Yang Y , WatersJB, FrühK, PetersonPA: Proteasomes are regulated by interferon gamma: implications for antigen processing. Proc Natl Acad Sci U S A89, 4928–4932 (1992))| false
• Search Google Scholar
• Export Citation

Ferrington DA , Gregerson DS: Immunoproteasomes: Structure, function, and antigen presentation. Prog Mol Biol Transl Sci 109, 75–112 (2012)

Ferrington DA , GregersonDS: Immunoproteasomes: Structure, function, and antigen presentation. Prog Mol Biol Transl Sci109, 75–112 (2012))| false
• Search Google Scholar
• Export Citation

Seifert U , Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schröter F, Prozorovski T, Lange N, Steffen J, Rieger M, Kuckelkorn U, Aktas O, Kloetzel P-M, Krüger E: Immunoproteasomes preserve protein homeostasis upon interferoninduced oxidative stress. Cell 142, 613–624 (2010)

Seifert U , BialyLP, EbsteinF, Bech-OtschirD, VoigtA, SchröterF, ProzorovskiT, LangeN, SteffenJ, RiegerM, KuckelkornU, AktasO, KloetzelP-M, KrügerE: Immunoproteasomes preserve protein homeostasis upon interferoninduced oxidative stress. Cell142, 613–624 (2010))| false
• Search Google Scholar
• Export Citation

Yun YS , Kim KH, Tschida B, Sachs Z, Noble-Orcutt KE, Moriarity BS, Ai T, Ding R, Williams J, Chen L, Largaespada D, Kim D-H: mTORC1 coordinates protein synthesis and immunoproteasome formation via PRAS40 to prevent accumulation of protein stress. Mol Cell 61, 625–639 (2016)

Yun YS , KimKH, TschidaB, SachsZ, Noble-OrcuttKE, MoriarityBS, AiT, DingR, WilliamsJ, ChenL, LargaespadaD, KimD-H: mTORC1 coordinates protein synthesis and immunoproteasome formation via PRAS40 to prevent accumulation of protein stress. Mol Cell61, 625–639 (2016))| false
• Search Google Scholar
• Export Citation

Mishto M , Liepe J, Textoris-Taube K, Keller C, Henklein P, Weberruß M, Dahlmann B, Enenkel C, Voigt A, Kuckelkorn U, Stumpf MPH, Kloetzel PM: Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur J Immunol 44, 3508–3521 (2014)

Mishto M , LiepeJ, Textoris-TaubeK, KellerC, HenkleinP, WeberrußM, DahlmannB, EnenkelC, VoigtA, KuckelkornU, StumpfMPH, KloetzelPM: Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur J Immunol44, 3508–3521 (2014))| false
• Search Google Scholar
• Export Citation

Toes REM , Nussbaum AK, Degermann S, Schirle M, Emmerich NPN, Kraft M, Laplace C, Zwinderman A, Dick TP, Müller J, Schönfisch B, Schmid C, Fehling H-J, Stevanovic S, Rammensee HG, Schild H: Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 194, 1–12 (2001)

Toes REM , NussbaumAK, DegermannS, SchirleM, EmmerichNPN, KraftM, LaplaceC, ZwindermanA, DickTP, MüllerJ, SchönfischB, SchmidC, FehlingH-J, StevanovicS, RammenseeHG, SchildH: Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med194, 1–12 (2001))| false
• Search Google Scholar
• Export Citation

Basler M , Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, Kirk CJ: Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 6, 226–38 (2014)

Basler M , MundtS, MuchamuelT, MollC, JiangJ, GroettrupM, KirkCJ: Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med6, 226–38 (2014))| false
• Search Google Scholar
• Export Citation

Ebstein F , Kloetzel P-M, Krüger E, Seifert U: Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol Life Sci CMLS 69, 2543–2558 (2012)

Ebstein F , KloetzelP-M, KrügerE, SeifertU: Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol Life Sci CMLS69, 2543–2558 (2012))| false
• Search Google Scholar
• Export Citation

Muchamuel T , Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, Groettrup M: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15, 781–787 (2009)

Muchamuel T , BaslerM, AujayMA, SuzukiE, KalimKW, LauerC, SylvainC, RingER, ShieldsJ, JiangJ, J, ShwonekP, ParlatiF, DemoSD, BennettMK, KirkCJ, GroettrupM: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med15, 781–787 (2009))| false
• Search Google Scholar
• Export Citation

Kalim KW , Basler M, Kirk CJ, Groettrup M: Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 189, 4182–4193 (2012)

Kalim KW , BaslerM, KirkCJ, GroettrupM: Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol189, 4182–4193 (2012))| false
• Search Google Scholar
• Export Citation

Hensley SE , Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W, Bennink JR, Yewdell JW: Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. J Immunol 184, 4115–4122 (2010)

Hensley SE , ZankerD, DolanBP, DavidA, HickmanHD, EmbryAC, SkonCN, GrebeKM, GriffinTA, ChenW, BenninkJR, YewdellJW: Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. J Immunol184, 4115–4122 (2010))| false
• Search Google Scholar
• Export Citation

Basler M , Mundt S, Bitzer A, Schmidt C, Groettrup M: The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol 33, S74–9 (2015)

Basler M , MundtS, BitzerA, SchmidtC, GroettrupM: The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol33, S74–9 (2015))| false
• Search Google Scholar
• Export Citation

Liu H , Wan C, Ding Y, Han R, He Y, Xiao J, Hao J: PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th 17-cell differentiation and regulating cytokine production. FASEB J 31, 1756–1766 (2017)

Liu H , WanC, DingY, HanR, HeY, XiaoJ, HaoJ: PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing T_h 17-cell differentiation and regulating cytokine production. FASEB J31, 1756–1766 (2017))| false
• Search Google Scholar
• Export Citation

Basler M , Dajee M, Moll C, Groettrup M, Kirk CJ: Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol Baltim Md 1950 185, 634–641 (2010)

Basler M , DajeeM, MollC, GroettrupM, KirkCJ: Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol Baltim Md 1950185, 634–641 (2010))| false
• Search Google Scholar
• Export Citation

Vachharajani N , Joeris T, Luu M, Hartmann S, Pautz S, Jenike E, Pantazis G, Prinz I, Hofer MJ, Steinhoff U, Visekruna A: Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7. Oncotarget [Epub ahead of print], doi: 10.18632/oncotarget.14579 (2017)

Vachharajani N , JoerisT, LuuM, HartmannS, PautzS, JenikeE, PantazisG, PrinzI, HoferMJ, SteinhoffU, VisekrunaA: Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7. Oncotarget [Epub ahead of print], doi: 10.18632/oncotarget.14579 (2017))| false
• Search Google Scholar
• Export Citation

Zaiss DMW , Bekker CPJ, Grone A, Lie BA, Sijts AJAM: Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol 187, 2302–2309 (2011)

Zaiss DMW , BekkerCPJ, GroneA, LieBA, SijtsAJAM: Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol187, 2302–2309 (2011))| false
• Search Google Scholar
• Export Citation

Wehenkel M , Ban J-O, Ho Y-K, Carmony KC, Hong JT, Kim KB: A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer 107, 53–62 (2012)

Wehenkel M , BanJ-O, HoY-K, CarmonyKC, HongJT, KimKB: A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer107, 53–62 (2012))| false
• Search Google Scholar
• Export Citation

Kuhn DJ , Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ: Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113, 4667 (2009)

Kuhn DJ , HunsuckerSA, ChenQ, VoorheesPM, OrlowskiM, OrlowskiRZ: Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood113, 4667 (2009))| false
• Search Google Scholar
• Export Citation

Banker G , Goslin K: Developments in neuronal cell culture. Nature 336, 185–186 (1988)

Banker G , GoslinK: Developments in neuronal cell culture. Nature336, 185–186 (1988))| false
• Search Google Scholar
• Export Citation

McLean IW , Nakane PK: Periodate-lysine-paraformaldehyde fixative. A new fixation for immunoelectron microscopy. J Histochem Cytochem 22, 1077–83 (1974)

McLean IW , NakanePK: Periodate-lysine-paraformaldehyde fixative. A new fixation for immunoelectron microscopy. J Histochem Cytochem22, 1077–83 (1974))| false
• Search Google Scholar
• Export Citation

Staff NP , Podratz JL, Grassner L, Bader M, Paz J, Knight AM, Loprinzi CL, Trushina E, Windebank AJ: Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. NeuroToxicology 39, 124–131 (2013)

Staff NP , PodratzJL, GrassnerL, BaderM, PazJ, KnightAM, LoprinziCL, TrushinaE, WindebankAJ: Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. NeuroToxicology39, 124–131 (2013))| false
• Search Google Scholar
• Export Citation

Zheng H , Xiao WH, Bennett GJ: Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol 238, 225–234 (2012)

Zheng H , XiaoWH, BennettGJ: Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol238, 225–234 (2012))| false
• Search Google Scholar
• Export Citation